Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRP-2 Peptide Vaccine +/- IL-2 in Metastatic Melanoma
NCT00022438Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2001
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trp-2:180-188 peptide in melanoma (3 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical Response Rate. Started Jun 2001; status: completed.
02
Drugs
trp-2:180-188 peptide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00022438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022438.